Issue

Vol. 65 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Indole itself and its novel derivative affect PML cells proliferation via controlling the expression of cell cycle genes

https://doi.org/10.14715/cmb/2019.65.3.6
Mojgan Karimabad Noroozi
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Mehd Mahmoodi
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Abdollah Jafarzadeh
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Ali Darehkordi
Department of Chemistry, Faculty of Science, Vali-e-Asr University of Rafsanjan, Rafsanjan, Iran
Mohammad Reza Hajizadeh
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Hossein Khorramdelazad
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Ahmad Reza Sayadi
Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Soudeh Khanamani Falahati-pour
Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Gholamhossein Hassanshahi
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Corresponding Author(s) : Mojgan Karimabad Noroozi

mojgannourozi@yahoo.com

Cellular and Molecular Biology, Vol. 65 No. 3: Issue 3

Abstract

Recently the role of indole and pyran rings in carcinogenesis has been well studied. Here we studied the effects and the possible mechanisms of the action of basal indole (I3A) and its novel indole derivative (C19H15F3N2O) on inhibition of proliferation cells in acute promyelocytic leukemia NB4 cell line by examining the expression of cell cycle genes. We treated NB4 cells with concentration of C19H15F3N2O for 24-72 h. The MTT and PI/Annexin V examinations were employed for assessment of the proliferation and apoptosis of NB4 cells. Both of Cyclin D and P21 were detected by the Real-time PCR. The western blotting analysis was also performed to show the protein levels for P21. A difference was regarded significant if p-value was less than 0.05. MTT assay showed that 15.12-1000 µg/mL C19H15F3N2O caused a time and concentration-dependent inhibition of NB4 cell proliferation. Exposure to higher concentrations of C19H15F3N2O resulted in significantly increased apoptosis rate in NB4 cells. RT PCR showed that C19H15F3N2O has up-regulated the expression of P21 and down-regulated the expression of Cyclin D. Western blotting experiments also demonstrated that the P21 expression in C19H15F3N2O treated cells has significantly increased, where compared with either untreated control cells or I3A treated cells. This newly (C19H15F3N2O) was able to inhibit NB4 cells proliferation and causes apoptosis of these cells more than I3A, and these effects are probably facilitated via cell cycle arrest. C19H15F3N2O might probably be introduced as a promising organic therapeutic reagent against APL.  

Keywords

C19H15F3N2O Gene Cancer Flow cytometry Real-time PCR Western blot.
Noroozi, M. K., Mahmoodi, M., Jafarzadeh, A., Darehkordi, A., Hajizadeh, M. R., Khorramdelazad, H., Sayadi, A. R., Falahati-pour, S. K., & Hassanshahi, G. (2019). Indole itself and its novel derivative affect PML cells proliferation via controlling the expression of cell cycle genes. Cellular and Molecular Biology, 65(3), 41–47. https://doi.org/10.14715/cmb/2019.65.3.6
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Hiebert SW, Lipp M, Nevins JR. E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor. Proceedings of the National Academy of Sciences. 1989;86(10):3594-8.
  2. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood reviews. 2003;17(2):71-97.
  3. Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505-15.
  4. Primo MN, Bak RO, Schibler B, Mikkelsen JG. Regulation of pro-inflammatory cytokines TNFα and IL24 by microRNA-203 in primary keratinocytes. Cytokine. 2012;60(3):741-8.
  5. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proceedings of the National Academy of Sciences. 2008;105(50):19750-5.
  6. Moiseeva EP, Heukers R. Indole-3-carbinol-induced modulation of NF-κB signalling is breast cancer cell-specific and does not correlate with cell death. Breast cancer research and treatment. 2008;109(3):451-62.
  7. Cram EJ, Liu BD, Bjeldanes LF, Firestone GL. Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. Journal of Biological Chemistry. 2001;276(25):22332-40.
  8. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Fibroblasts and their transformations: The connective-tissue cell family. 2002.
  9. Aubry C, Patel A, Mahale S, Chaudhuri B, Maréchal J-D, Sutcliffe MJ, et al. The design and synthesis of novel 3-[2-indol-1-yl-ethyl]-1H-indole derivatives as selective inhibitors of CDK4. Tetrahedron letters. 2005;46(9):1423-5.
  10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-25.
  11. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes & development. 1993;7(7a):1126-32.
  12. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, et al. Inhibition of cyclin-dependent kinases by p21. Molecular biology of the cell. 1995;6(4):387-400.
  13. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (New York, NY). 1998;282(5393):1497-501.
  14. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803-15.
  15. Adrover E, Maestro ML, Sanz-Casla MT, del Barco V, Cerdan J, Fernandez C, et al. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. British journal of cancer. 1999;81(1):122-6.
  16. Gasparini G. Prognostic variables in node-negative and node-positive breast cancer”editorial. Prognostic variables in node-negative and node-positive breast cancer: Springer; 1998. p. 411-21.
  17. Rey MJ, Fernández PL, Jares P, Muñoz M, Nadal A, Peiró N, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. The Journal of pathology. 1998;184(3):265-71.
  18. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nature Reviews Cancer. 2009;9(6):400-14.
  19. Aaltomaa S, Lipponen P, Eskelinen M, Ala"Opas M, Kosma V. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. The Prostate. 1999;39(1):8-15.
  20. Biankin AV, Kench JG, Morey AL, Lee C-S, Biankin SA, Head DR, et al. Overexpression of p21WAF1/CIP1 is an early event in the development of pancreatic intraepithelial neoplasia. Cancer research. 2001;61(24):8830-7.
  21. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994;84(11):3781-4.
  22. Shiohara M, Koike K, Komiyama A, Koeffler HP. p21WAF1 mutations and human malignancies. Leukemia & lymphoma. 1997;26(1-2):35-41.
  23. Balbí­n M, Hannon GJ, Pendás AM, Ferrando AA, Vizoso F, Fueyo A, et al. Functional analysis of a p21WAF1, CIP1, SDI1 mutant (Arg94→ Trp) identified in a human breast carcinoma Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. Journal of Biological Chemistry. 1996;271(26):15782-6.
  24. Bahl R, Arora S, Nath N, Mathur M, Shukla NK, Ralhan R. Novel polymorphism in p21waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene. 2000;19(3):323.
  25. Cazier J-B, Rao S, McLean C, Walker A, Wright B, Jaeger E, et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nature communications. 2014;5.
  26. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21Cip1 and p27Kip1 CDK ‘inhibitors' are essential activators of cyclin D"dependent kinases in murine fibroblasts. The EMBO journal. 1999;18(6):1571-83.
  27. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes & development. 1997;11(7):847-62.
  28. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell proliferation. 2003;36(3):131-49.
  29. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 1983;33(2):389-96.
  30. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369(6482):669.
  31. Buckley MF, Sweeney K, Hamilton J, Sini R, Manning D, Nicholson R, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8(8):2127-33.
  32. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer research. 1994;54(7):1812-7.
  33. An H-X, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. The American journal of pathology. 1999;154(1):113-8.
  34. Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, et al. Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Research. 2013;15(3):R49.
  35. Kitagawa M, Higashi H, Jung H-K, Suzuki-Takahashi I, Ikeda M, Tamai K, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. The EMBO journal. 1996;15(24):7060.
  36. Hanahan D, Weinberg RA. The hallmarks of cancer. cell. 2000;100(1):57-70.
  37. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer cell. 2002;2(2):103-12.
  38. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes & development. 2000;14(7):804-16.
  39. Yam C, Fung T, Poon R. Cyclin A in cell cycle control and cancer. Cellular and Molecular Life Sciences. 2002;59(8):1317-26.
  40. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, et al. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 1996;12(6):1173-80.
  41. De Santi M, Galluzzi L, Lucarini S, Paoletti MF, Fraternale A, Duranti A, et al. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Research. 2011;13(2):R33.
  42. Darehkordi A, Rahmani F, Hashemi V. Synthesis of new trifluoromethylated indole derivatives. Tetrahedron Letters. 2013;54(35):4689-92.
  43. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-25.
  44. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer research. 2005;65(10):3980-5.
  45. Child ES, Mann DJ. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell cycle. 2006;5(12):1313-9.
  46. Rössig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells. Molecular and cellular biology. 2001;21(16):5644-57.
  47. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell cycle. 2005;4(9):1201-15.
  48. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer research. 2009;69(16):6565-72.
  49. Jung H, Shin J-H, Park Y-S, Chang M-S. Ankyrin repeat-rich membrane spanning (ARMS)/Kidins220 scaffold protein regulates neuroblastoma cell proliferation through p21. Molecules and cells. 2014;37(12):881-7.
  50. Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, et al. 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chemico-biological interactions. 2010;186(3):255-66.
  51. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. Journal of Biological Chemistry. 1998;273(7):3838-47.
  52. Garcia HH, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. Journal of Biological Chemistry. 2005;280(10):8756-64.
  53. Ryu C-K, Lee JY, Park R-E, Ma M-Y, Nho J-H. Synthesis and antifungal activity of 1H-indole-4, 7-diones. Bioorganic & medicinal chemistry letters. 2007;17(1):127-31.
  54. Blum CA, Xu M, Orner GA, Fong AT, Bailey GS, Stoner GD, et al. β-Catenin mutation in rat colon tumors initiated by 1, 2-dimethylhydrazine and 2-amino-3-methylimidazo [4, 5-f] quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol. Carcinogenesis. 2001;22(2):315-20.
  55. Gul W, Hamann MT. Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life sciences. 2005;78(5):442-53.
  56. Safe S, Papineni S, Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis (3"²-indolyl) methane and synthetic analogs. Cancer letters. 2008;269(2):326-38.
  57. Firestone GL, Sundar SN. Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Molecular Endocrinology. 2009;23(12):1940-7.
  58. Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. The Journal of nutrition. 2003;133(7 Suppl):2448s-55s.
  59. Zhou T, Li G, Cao B, Liu L, Cheng Q, Kong H, et al. Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells. Cell death & disease. 2013;4(2):e515.
  60. Table 2 The changes in viability of NB4 cells treated with different concentrations of I3C and C19H15F3N2O after 24, 48 and 72 h, using MTT method. A# * Significant in compared different concentrations C19H15F3N2O with I3C group (P < 0.05)
  61. .
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 806 Download : 368